Key result
MDM2 inhibition reduces Alk1-induced arteriovenous malformations by targeting SOX17-driven abnormal endothelial differentiation.
Why the study?
Does inhibition of SOX17 or MDM2 prevent ALK1-deficient arterial endothelial cells from acquiring lymphatic characteristics and reduce arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia type 2?
Does inhibition of SOX17 or MDM2 prevent ALK1-deficient arterial endothelial cells from acquiring lymphatic characteristics and reduce arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia type 2?
Answers are grounded in this paper and cite their sources.
Identifies a novel SOX17- and MDM2-dependent transition of ALK1-depleted arterial endothelial cells into arterial-lymphatic-like cells that drives arteriovenous malformations in HHT2, revealing MDM2 inhibition as a potential therapeutic strategy.
BACKGROUND: Arteriovenous malformations (AVMs) are characteristic of hereditary hemorrhagic telangiectasia. Loss-of-function mutations in the activin receptor‐like kinase 1 ( Alk1 ) are linked to hemorrhagic telangiectasia type 2. METHODS: Endothelial-specific deletion of Alk1, endothelial lineage tracing, transcriptomics of single-cell analysis, and electron microscopy were performed to examine the vascular phenotype and characteristics of ALK1-deficient endothelial cells (ECs) after EC-specific Alk1 deletion. Ischemia assays were used to examine the cell capacity for vascular malformation. Connectivity Map with transcriptomic analysis was applied to identify chemical compounds. Specific methods for arteriovenous malformations, such as micro–computed tomography, with other molecular and cell biological tools were also performed. RESULTS: We performed endothelial-specific deletion of Alk1 in mice and found severe arteriovenous malformations and vascular leakage. The transcriptomics of single-cell analysis revealed a new distinctive cell cluster formed after Alk1 deletion where the cells coexpressed arterial and lymphatic endothelial markers. The analysis projected that these cells potentially originated from arterial ECs after Alk1 deletion. This new population was referred to as arterial-lymphatic-like ECs according to its cellular markers, and its appearance was validated in the pulmonary small arteries after Alk1 deletion. Transplantation of these cells caused vascular malformations. Endothelial lineage tracing confirmed that these new arterial-lymphatic-like ECs were derived from ALK1 depleted ECs, potentially arterial ECs. We discovered that SOX17 (SRY-box transcription factor 17) induction was responsible for the derivation of these arterial-lymphatic-like ECs. We showed that direct binding of MDM2 (mouse double minute 2) was required for Sox17 to execute this activity. Inhibition of MDM2 reduced the arteriovenous malformations in the mouse model. CONCLUSIONS: Together, our studies revealed the mechanistic underpinnings of ALK1 signaling in regulating the endothelial phenotype and provided possibilities for new therapeutic strategies in hemorrhagic telangiectasia type 2.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied Hereditary hemorrhagic telangiectasia type 2 (HHT2) and arteriovenous malformations (AVMs). Endothelial-specific Alk1 deletion and subsequent MDM2 inhibition with HLI373 or Sox17 shRNA vs. Alk1 flox/flox or VE-cadherin cre/ERT2 littermate control mice, and untreated tamoxifen-induced VE-cadherin cre/ERT2 Alk1 flox/flox mice was evaluated on Formation and reduction of pulmonary arteriovenous malformations (niduses), vascular leakage, and appearance of arterial-lymphatic-like endothelial cells (p=<0.0001). Endothelial-specific Alk1 deletion induced SOX17-driven arterial-lymphatic-like endothelial cells causing arteriovenous malformations, which were significantly reduced by MDM2 inhibition with HLI373.
Synapse has enriched 10 related papers. Consider them for comparative context: